Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA ...

Medtronic (MDT) announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density mapping ...

Medtronic said the Food and Drug Administration approved its Affera mapping and ablation system with sphere-9 catheter.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug ...

Medtronic (NYSE: MDT) announced today that the FDA approved an early feasibility study to evaluate its Affera system for ...

The FDA approved an early feasibility study of Medtronic’s Affera mapping and ablation system and Sphere-9 catheter in ...

The study aims to assess the Catheter and Affera system in patients who have ventricular tachycardia (VT) due to scarring ...

Affera, a 14-year-old camper in Sarasota, said she grew up watching her dad abuse alcohol. Through camp, she said she has learned that her dad's substance abuse issues are, "not because he doesn't ...

Medtronic plc received U.S. FDA approval to undertake an early feasibility study of its dual-energy Affera cardiac ablation system in sustained ventricular tachycardia. Affera combines both ...

Madi, left, and Affera write letters to addiction at Camp Mariposa in Sarasota, Florida. Katie Kindelan/ABC News In some cases, like Madi's, campers have lost a parent to substance abuse ...

Shares in Boston Scientific (NYSE:BSX) fell more than 1% in premarket trading Friday after analysts at Needham & Co.

Medtronic has announced US Food and Drug Administration (FDA) approval to conduct an early feasibility study using the Affera Mapping and Ablation System for sustained VT, a serious heart condition.